Have any questions? 706-721-6582 or cts@augusta.edu
- (ACCUTE) Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of AB103 as Compared to Placebo in Patients with Necrotizing Soft Tissue Infections (NSTI) ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)
Clinical Trial
(ACCUTE) Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of AB103 as Compared to Placebo in Patients with Necrotizing Soft Tissue Infections (NSTI) ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)
This study is for patients who have a necrotizing soft tissue infection and will have surgery for this. With this kind of very serious infection, tissue is dying. This study will compare treating these infections with a new drug, AB103, to a placebo (fake treatment) to see how well it works and how safe it is for patients.
Eligibility Criteria
- must be 12 years of age or older must have a diagnosis of necrotizing soft tissue infection confirmed by the patient's surgeon have a body mass index less than 51 if female, must not be pregnant or become pregnant, and must not be breastfeeding.
RESEARCH. INNOVATION. DISCOVERY.